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biotic efficacy has been shown for 
therapy with the intravenous anti-leu- 
kocyte integrin antibody in the animal 
model. 
The therapies developed in experi- 
mental models have proved highly ef- 
ficacious in humans, forming a strong 
experimental and clinical data base for 
considering recommendation of a new 
standard for therapy of bacterial men- 
ingitis in children and adults that in- 
cludes anti-inflammatory agents. It 
remains to be determined which single 
agent or combination of agents will 
yield the most benefit. New trials in 
neonates will determine if this group 
will also derive benefit from adjunct 
therapy as predicted by experimental 
evidence. What is certain is that a 
new avenue finally exists to decrease 
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the up to 30% mortality in children 
and 50% mortality in neonates who 
contract bacterial meningitis. 
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Haemophilus influenzae type B is a 
major pathogen in children, causing 
serious infections such as meningitis, 
facial cellulitis, pneumonia, septic ar- 
thritis, and epiglottitis in approxi- 
mately 20,000 children in the United 
States (U.S.) annually. In spite of the 
availability of good antibiotic therapy, 
the mortality rate of H. influenzae 
type B meningitis, the most life- 
threatening of these infections, is 5% 
to 10%. In addition, significant neu- 
rologic sequelae occur in many chil- 
dren following H. influenzae 
meningitis. 
In order to prevent infection with 
H. influenzae type B, several vaccines 
have been licensed for use in chil- 
dren. The first series of these vac- 
cines, which were introduced in 1985, 
contained only the purified capsular 
material, polyribosylribose phosphate 
or PRP. Extensive experience with 
the plain PRP vaccines demonstrated 
their poor immunogenicity in young 
children <24 months of age. How- 
ever, the majority of H. influenzae 
infections occur in younger children 
with the peak incidence at about 9 to 
11 months of age. In attempting to 
develop vaccines that would be effec- 
tive at younger ages, the newer H. 
influenzae type B vaccines have used 
the plain PRP polysaccharide conju- 
gated to various proteins. The first 
H. influenzae type B protein conju- 
gate vaccine became available in 1987 
with the licensure PRP-D, which con- 
tained plain PRP conjugated to diph- 
theria toxoid, and has been marketed 
under the name PROHIBIT by Con- 
naught Laboratories. More recently, 
PRP-CRM, which contains smaller 
PRP molecules or oligosaccharides, 
conjugated to a mutant diphtheria 
protein called CRM197 has been li- 
censed and is marketed as HIB- 
TITER by Praxis Biologics. A third 
conjugate vaccine, PRP-NOMP, 
called PEDVAX-HIB and made by 
Merck, Sharp, and Dohme, has most 
recently been licensed by the Food 
and Drug Administration. This vac- 
cine contains plain PRP conjugated to 
an outer membrane protein of Neis- 
seria meningitidis group B. All three 
of the conjugate vaccines have been 
licensed by the FDA for use in 18- to 
71-month-old children, with permis- 
sive use at 15 months. 
A major concern in the develop- 
ment of new vaccine products is their 
safety. Experience with PRP-D has 
shown a few relatively minor reac- 
tions. The number and types of ad- 
verse reactions appear to be no 
different from those observed with the 
older, plain PRP vaccine, and include 
mild irritability and tenderness at the 
injection site in < 15% of recipients; 
and low-grade fever, mild erythema, 
and swelling at the injection site in 
<2% of recipients. Less information 
is available on reactions associated 
with PRP-CRM and PRP-NOMP, but 
they appear to be no different from 
those following PRP-D. Thus, H. in- 
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fluenzae type B conjugate vaccines 
appear to be very safe in terms of 
vaccine-related reactions. 
Following licensure of the plain 
PRP vaccine, preliminary observations 
of vaccine failures suggested a pos- 
sible increase in the frequency of H. 
influenzae type B infections during the 
first week after vaccination. These 
rare, early cases may have represented 
real vaccine-associated infections or 
merely the background incidence of 
H. influenzae infections. A few may 
also have resulted from high-risk situ- 
ations, such as exposure to a child 
with H. influenzae infection. Al- 
though it is not clear that these infec- 
tions were truly related to receipt of 
vaccine, a mechanism has been pro- 
posed to explain possible suscepti- 
bility to H. influenzae type B infection 
soon after vaccination. In individuals 
with preexisting antibody against 
PRP, a decrease in the level of PRP 
antibodies has been shown during the 
first several days following vaccina- 
tion with plain PRP. This decrease is 
then followed by an increase in anti- 
body as the vaccinee develops an im- 
mune response to the vaccine. The 
decline in PRP antibody level is prob- 
ably due to the formation of immune 
complexes of preformed antibody and 
circulating vaccine antigen. Further- 
more, the decline in serum antibodies 
has been correlated with the appear- 
ance of vaccine antigen in the urine, 
probably reflecting the presence of 
circulating vaccine antigen. PRP an- 
tigenuria has been observed immedi- 
ately following vaccination with both 
PRP-D and PRP-NOMP. However, 
it has not been observed following 
PRP-CRM, possibly because the small 
carbohydrate in this vaccine is not 
recognized by the latex agglutination 
assay used to detect antigenuria. 
In considering antibody levels fol- 
lowing vaccination with the conjugate 
vaccines, some individuals who have 
preexisting H. influenzae antibodies 
have demonstrated a decrease in these 
antibodies following PRP-D and 
PRP-NOMP vaccination. Data have 
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not been presented for review on PRP 
antibody levels following PRP-CRM 
vaccination. In terms of actual H. in- 
[luenzae type B infections during the 
first week following conjugate vaccine 
use, only a very few early cases have 
occurred following PRP-D vaccine 
and they may represent background. 
Out of 52,000 children in the U.S. 
receiving PRP-D, 2 experienced H. 
influenzae type B disease on the 
second day following vaccination. In 
Finland, no cases were seen in the 
first week following PRP-D vaccina- 
tion in 57,000 children. Neither 
PRP-CRM nor PRP-NOMP has been 
used extensively enough for an accu- 
rate assessment. 
Another area of major concern in 
the evaluation of vaccines is efficacy. 
Two methods have been used to eval- 
uate the efficacy of a vaccine: immu- 
nogenicity and protection. In studies 
of immunogenicity, pre- and postvac- 
cine antibody levels are measured and 
compared. In protection studies, the 
vaccine is given and subsequent oc- 
currence of disease is monitored. In 
evaluating H. influenzae type B vac- 
cine, protection studies are logistically 
difficult because the disease is rela- 
tively infrequent and large numbers of 
children and long follow-up periods 
are required to completely evaluate 
protection. The ideal protection 
studies are the placebo-controlled 
trials such as those that have been 
done in Finland and in Alaska. Be- 
cause of these logistic problems, the 
FDA has licensed the H. influenzae 
vaccines in the U.S. based on their 
immunogenicity; then postmarketing 
protection surveys have been con- 
ducted. Many questions remain con- 
cerning the correlation of 
immunogenicity and antibody levels 
with protection. A level of >0.15 
Ixg/mL of natural antibodies or > 1 
ixg/mL vaccine-induced antibodies has 
been suggested as reflecting protec- 
tive levels. However, this is probably 
too simplistic. Usual antibody assays 
measure total anti-PRP antibody, but 
total antibody contains antibodies that 
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differ in immunoglobulin class, in 
immunoglobulin G subclass, in 
binding affinity, and in epitope speci- 
ficity. These parameters can vary 
considerably from child to child and 
recent Finnish data suggest a poor 
correlation between total antibody 
level and protection. Postmarketing 
evaluation of PRP-D and PRP-CRM 
is currently in progress. Vaccine 
failures appear to be much less 
common with PRP-D than with plain 
PRP; information is not yet available 
on the PRP-CRM. 
A confusing observation with plain 
PRP vaccine was the variability of ef- 
ficacy seen in several areas within the 
U.S. and also the lower efficacy in 
the U.S. than was expected based on 
the old Finland trials. In fact, PRP 
vaccine appeared to have no efficacy 
in Minnesota. More recent data show 
that, since the introduction of PRP-D, 
no vaccine failures have occurred in 
Minnesota. In summary, all H. in- 
fluenzae type B conjugate vaccines 
appear to be equally very effective in 
the U.S. when given at 18 months of 
age and probably at 15 months as 
well. Studies to document that effi- 
cacy are currently in progress. 
Because H. influenzae infections 
occur in children as young as 6 to 8 
weeks, a major goal is to develop 
vaccines that will be effective at this 
early age. Toward that goal, the FDA 
is deliberating over the immunoge- 
nicity data of the conjugate vaccines 
and considering licensure for younger 
children. In addition, studies are in 
progress evaluating multiple doses of 
conjugate vaccine, beginning at early 
ages. In a recent study from Finland, 
after three doses of PRP-D by 6 
months, efficacy was 89%. Disap- 
pointingly, however, in a recent study 
from Alaska, also after three doses of 
PRP-D by 6 months, the efficacy was 
only 37%. Studies in progress are 
evaluating PRP-CRM and PRP- 
NOMP at these early ages and the re- 
suits should be available by the end of 
1990. lmmunogenicity results sug- 
gest that these two vaccines may be 
more effective at earlier ages than 
PRP-D. 
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CASE REPORT 
A 16-year-old white female presented 
to her local physician 1 week after 
stepping on a nail through her tennis 
shoe. The patient sought no medical 
care immediately following the injury, 
but reportedly cleaned the wound. 
On presentation, she had a low-grade 
fever (101.2°F), a limp, local tender- 
ness over the puncture wound site, 
and complaints of throbbing foot 
pain. The foot was swollen and red 
over the plantar surface with a 2 × 3 
cm area of cellulitis. The local phy- 
sician began ceftriaxone, 2 g twice a 
day, for foot cellulitis and followed 
her as an outpatient. On day 4 of 
therapy, the foot had become dif- 
fusely swollen, cool to touch, mark- 
edly tender, and the area of cellulitis 
had grown to4  × 5cm.  She had 
also begun to experience right upper 
quadrant pain, nausea, vomiting, and 
anorexia on the morning of day 4 of 
ceftriaxone therapy. She was referred 
for an unresponsive foot cellulitis. 
On referral, the examination of the 
foot revealed an area of cellulitis with 
fluctuance and marked tenderness 
over the second metatarsophalangeal 
joint with movement. The admitting 
physician made the tentative diagnosis 
of Pseudomonas osteochondritis/ 
septic arthritis and a subcutaneous ab- 
scess/cellulitis probably due to a 
staphylococcal wound infection. The 
ceftriaxone was discontinued and she 
was treated with intravenous nafcillin, 
1 g every 6 hours, and tobramycin, 60 
mg every 8 hours. 
Orthopedic surgery was consulted 
and she was taken to surgery on the 
same day. A subcutaneous abscess 
containing 4 to 6 mL of purulent 
drainage grew Pseudomonas aeru- 
ginosa and Staphylococcus aureus. 
The second metatarsal head was in- 
volved and the metatarsophalangeal 
joint was infected. Cultures of the 
cartilage/bone scrapings and joint 
fluid grew P. aeruginosa. Both 
Pseudomonas isolates were sensitive 
to tobramycin and resistant to cef- 
triaxone. 
Further investigation of the abdom- 
inal complaints revealed a tender right 
upper quadrant and positive Murphy's 
sign. Her liver function studies were 
elevated (~/GT, ten times normal; 
SGOT, two times normal). An ultra- 
sound of her liver and gallbladder re- 
vealed hyperechogenic sludge in the 
gallbladder. 
She promptly defervesced postop- 
eratively with resolution of her pain 
and foot complaints and good healing; 
she was discharged from the hospital 
after 7 days of intravenous antibiotics 
on an additional 3 days of oral di- 
cloxacillin for the resolving cellulitis. 
Seven days after discontinuation of 
ceftriaxone, she had resolved her an- 
orexia, nausea, vomiting, and abdom- 
inal pain. Her liver function tests 
and gallbladder ultrasound had re- 
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turned to normal by 8 weeks postdis- 
charge. 
Discussion 
This case report illustrates two impor- 
tant areas recently described in the 
literature. The issue of Pseudomonas 
osteochondritis following a nail punc- 
ture wound to the foot has recently 
been updated by a prospective, 10 
year evaluation of 77 patients. In this 
series, the emphasis of early recogni- 
tion from historical data and diagnosis 
by aggressive sampling for cultures 
was highlighted by the demonstration 
that Pseudomonas osteochondritis is a 
surgical disease. Following appro- 
priate drainage of subcutaneous ab- 
scesses, curettage of infected 
bone/cartilage, and drainage plus irri- 
gation of infected joints, these pa- 
tients were treated with intravenous 
anti-Pseudomonas antibiotics for 7.5 
+ 1.2 days with a successful out- 
come. Only two relapses (2/77) were 
found in 5.2 + 3.4 years follow-up 
with both relapses due to previously 
undiagnosed septic arthritis. These 
children were discharged requiring no 
antibiotic therapy for Pseudomonas. 
This is fortunate because no effective 
oral therapy with tissue penetration 
exists for children with the current re- 
strictions on the use of oral fluoro- 
quinolones. This prospective study 
follows the author's previous retro- 
